Resother Pharma ApS has divulged new N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists potentially useful for the treatment of chronic inflammation.
Perha Pharmaceuticals has discovered new pyrazolo[1,5-a]pyrimidine derivatives acting as adenosine A3 receptor antagonists potentially useful for the treatment of ulcerative colitis, atopic dermatitis, glaucoma, asthma, liver fibrosis, renal disorders, hearing loss and glioblastoma, among others.
“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. Secretomes refer to the collection of bioactive molecules secreted by cells in the extracellular space, including proteins, enzymes, growth factors and extracellular vesicles such as exosomes.
